RxDoctor Payments DataLook up a doctor →

Vijay Raja, MD

Interventional Cardiology · Little Rock, ARNPI 1265691976

Payments from drug & device makers

$105,897in general payments, 2019–2025

Across 470 payments — averaging $225.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$63K
  • Shockwave Medical, Inc$34K
  • Abiomed$3K
  • Boston Scientific$971
  • Edwards Lifesciences$948
  • Johnson & Johnson$940
  • plus $4K from 28 others
$319in research payments, 2019–2025

Across 5 payments — averaging $63.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$319

What the payments were for

  • Consulting fees$5501%
  • Speaking & faculty fees$26,40057%
  • Travel & lodging$7,76117%
  • Food & beverage$11,41425%
  • Education$100%
  • Other$2821%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$105,897 in reported general payments places this provider in the 95th percentile of 89 interventional cardiology providers in Arkansas.

See all interventional cardiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$600,987
Medicare patients
1,479
Services billed
8,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban568$500,081
XareltoRivaroxaban301$239,511
EntrestoSacubitril/Valsartan153$145,945
CamzyosMavacamten14$122,327
MultaqDronedarone Hcl96$81,460
Repatha SureclickEvolocumab119$74,981
FarxigaDapagliflozin Propanediol84$63,730
JardianceEmpagliflozin59$54,925
VerquvoVericiguat18$19,413
BrilintaTicagrelor24$16,087
Ranolazine ErRanolazine122$8,506
ClopidogrelClopidogrel Bisulfate738$6,933
Potassium Chloride385$6,507
Carvedilol866$5,258
Metoprolol Succinate637$5,230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$344$500,081568 claims
Johnson & JohnsonXarelto$940$239,511301 claims
NovartisEntresto$371$145,945153 claims
E.r. Squibb & Sons, L.L.C.Camzyos$298$122,32714 claims
Sanofi-aventis U.S. LLCMultaq$61$81,46096 claims
AstraZenecaFarxiga, Brilinta$171$79,817108 claims
Boehringer IngelheimJardiance$12$54,92559 claims
MerckVerquvo$466$19,41318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 89 interventional cardiology providers in Arkansas.

Other interventional cardiology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →